Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm, specializes in creating antibody-driven immunotherapeutic remedies primarily for various cancers. A cornerstone of its product pipeline is Mab AR 9.6, an advanced therapeutic candidate specifically designed to target truncated O-glycans on MUC16 for precise cancer treatment applications. The company's offerings further encompass Oregovomab, an anti-CA-125 antibody that has successfully completed Phase II clinical trials for the management of ovarian cancer. Beyond these specific agents, Quest PharmaTech is actively involved in the development, manufacturing, and commercialization of new immunotherapy products aimed at combating pancreatic cancer. The organization also diversifies its portfolio by utilizing proprietary transdermal delivery technologies to formulate products for dermatological conditions and wound healing. Additionally, it develops specialized skin-penetrating active molecules for use in both cosmetic and pharmaceutical goods. Rounding out its innovative efforts, Quest PharmaTech designs intricate combinatorial immunotherapies for cancer, employing monoclonal antibodies belonging to both immunoglobulin G and E classes.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
Revenue data limited
+392.8% YoY
YoY Growth Rate
Strong earnings growth
C$242,704/ year
↓ Declining (-26% vs prior year)
R&D spend declining — could signal cost-cutting or efficiency
5+ years
C$28M cash & investments at current burn rate
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
The share count has stayed roughly flat over this period — little dilution or buyback activity.
Diluted shares outstanding: 168.2M (2022) → 169.1M (2026)
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
Negative ROIC means the business is losing money on every dollar invested in it.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E under 10. The price tag is small relative to last year's profit.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
